We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Pushes Back Review of AbbVie’s Rinvoq for Psoriatic Arthritis
FDA Pushes Back Review of AbbVie’s Rinvoq for Psoriatic Arthritis
The FDA has extended its review period for AbbVie’s supplemental New Drug Application (sNDA) for Rinvoq (upadacitinib) as a treatment for adults with psoriatic arthritis.